

AXUMIN®
Fluciclovine F 18 Injection

Access and Reimbursement Information for Axumin

The purpose of this resource is to offer information to providers and payers regarding reimbursement for Axumin. Reimbursement information and processes will evolve over time, as they do with any prescription drug. Please visit www.axumin.com/access-reimbursement periodically for the most up-to-date information.

REIMBURSEMENT SUPPORT HOTLINE

Telephone
1-855-495-9200

Email
reimbursement@blueearthdx.com

Fax
1-877-309-7514

Expanded Hours of Operation: Telephone support is available Monday through Friday, from 9 AM to 8 PM EST.

NEW REIMBURSEMENT SUPPORT TO HELP PATIENTS ACCESS AXUMIN

- **Benefit investigation:** Investigation of patient insurance benefits, including deductible and copayments, and coverage status for Axumin and PET/CT, including insurance requirements and possible coverage restrictions
- **Prior authorization (PA) assistance:** Information on PA requirements*
- **Appeal assistance:** Information on appeals requirements for denied prior authorizations or denied claims*

ADDITIONAL SUPPORT OFFERED

- **Billing, coding, and claims information:** Assistance with questions specific to billing, coding, and claims submission for Axumin and PET*
- **Patient support:** Support with issues related to reimbursement coverage, claim submission, and payment denials

Patient enrollment → **Benefit investigation** → **Prior authorization assistance** → **Appeal assistance**

Practice submits patient enrollment form to helpline and is contacted within 24 hours

Helpline conducts benefit investigation and notifies practice within 24 to 48 hours

Helpline assists practice in understanding PA requirements, submits and follows up within 48 to 72 hours*

Helpline assists practice in understanding appeal requirements for a denied PA or claim

*Helpline provides information about PA/appeals requirements, submits PA forms completed by the provider to the payer.

This document contains factual information and is not intended to be legal or coding advice. Blue Earth Diagnostics does not guarantee coverage or reimbursement for Axumin. The information provided in this document is based upon current, general coding practices. The existence of billing codes does not guarantee coverage and payment. Payer policies vary and may change without notice. It is the providers' responsibility to determine and submit accurate information on claims. This includes submitting such as proper codes, modifiers, charges, and invoices for the services that were rendered. The coding on claims should reflect medical necessity and be consistent with the documentation in the patient's medical record.

Please see Axumin Important Safety Information on back.

Access and Reimbursement Information for Axumin

AXUMIN®
Fluciclovine F 18 Injection

INDICATION

Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

- Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
- Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
- Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
- Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Axumin Prescribing Information, also available at www.axumin.com.

BLUE EARTH DIAGNOSTICS
A Bracco Company

BEDPRC21-0079F 9/21